BriaCell's Q1 Loss Widens 42% on Soaring R&D Costs

TL;DR

**BriaCell is burning cash fast with R&D, making it a risky bet unless they secure significant new funding soon.**

AI Summary

BriaCell Therapeutics Corp. (BCTXZ) reported a significant increase in net loss for the three months ended October 31, 2025, reaching $8,278,328, up from $5,829,276 in the same period of 2024. This 42% increase was primarily driven by a substantial rise in research and development expenses, which climbed to $6,683,643 from $3,665,341 year-over-year. General and administrative expenses also increased to $1,639,300 from $1,487,491. The company's cash and cash equivalents plummeted to $2,714,012 as of October 31, 2025, from $10,493,808 on July 31, 2025, reflecting negative cash flow from operating activities of $7,704,796. Total assets decreased from $21,649,706 to $13,075,050 over the same period. BriaCell continues to advance its Bria-IMT targeted immunotherapy program for end-stage breast cancer to Phase 3, which has FDA approval, and is developing Bria-OTS and a soluble CD80 protein therapeutic. The accumulated deficit reached $119,953,129, and the company's ability to continue as a going concern is dependent on securing additional financing.

Why It Matters

BriaCell's escalating net loss and dwindling cash reserves raise significant concerns for investors, signaling a heightened need for capital in a competitive biotech landscape. The substantial increase in R&D expenses, while critical for advancing its Phase 3 breast cancer immunotherapy, is rapidly consuming its financial resources. This financial strain could impact the company's ability to fund ongoing clinical trials and bring its promising therapies to market, potentially affecting future revenue streams and employee job security. For customers, delays in drug development due to funding issues could mean longer waits for potentially life-saving treatments, while the broader market will watch closely to see if BriaCell can secure the necessary financing to avoid further dilution or operational setbacks.

Risk Assessment

Risk Level: high — BriaCell's accumulated deficit of $119,953,129 as of October 31, 2025, and negative cash flows from operating activities of $7,704,796 for the three months ended October 31, 2025, indicate severe financial distress. The company explicitly states that its ability to continue as a going concern is in "substantial doubt" without additional financing, despite raising $50.9 million in gross proceeds from equity financings in the year ended July 31, 2025.

Analyst Insight

Investors should exercise extreme caution and consider BriaCell a high-risk speculative investment. Monitor closely for announcements regarding new financing rounds, as the company's survival hinges on its ability to secure substantial capital to fund its ongoing Phase 3 clinical trials and operational expenses.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$ 13,075,050

total Debt

$ 406,873

net Income

$ -8,278,328

eps

$ -4.35

gross Margin

N/A

cash Position

$ 2,714,012

revenue Growth

N/A

Key Numbers

• $8,278,328 — Net loss for the period (Increased from $5,829,276 in 2024, a 42% increase)
• $6,683,643 — Research and development expenses (Increased from $3,665,341 in 2024, a 82% increase)
• $2,714,012 — Cash and cash equivalents (Decreased from $10,493,808 on July 31, 2025)
• $7,704,796 — Negative cash flow from operating activities (For the three months ended October 31, 2025)
• $119,953,129 — Accumulated deficit (As of October 31, 2025)
• $4.35 — Net loss per share (For the three months ended October 31, 2025)
• 1,883,906 — Common shares outstanding (As of December 11, 2025)
• $13,075,050 — Total assets (Decreased from $21,649,706 on July 31, 2025)

Key Players & Entities

• BriaCell Therapeutics Corp. (company) — registrant
• FDA (regulator) — approved Phase 3 study
• BC Therapeutics, Inc. (company) — investee
• Bria-IMT (company) — targeted immunotherapy program
• Bria-OTS (company) — personalized off-the-shelf immunotherapy
• Nasdaq Stock Market LLC (regulator) — exchange where securities are registered
• Toronto Stock Exchange (regulator) — exchange where securities are listed
• Chief Executive Officer (person) — Chief Operating Decision Maker

FAQ

Risk Factors

• Substantial increase in net loss and negative cash flow [high — financial]: The company reported a net loss of $8,278,328 for the three months ended October 31, 2025, a 42% increase from the prior year's $5,829,276. This was driven by a significant rise in R&D expenses to $6,683,643 from $3,665,341. Operating activities consumed $7,704,796 in cash, leading to a sharp decline in cash and cash equivalents from $10,493,808 to $2,714,012.
• Deteriorating cash position and going concern uncertainty [high — financial]: Cash and cash equivalents decreased by over $7.7 million in the quarter, ending at $2,714,012. The company's accumulated deficit has reached $119,953,129. BriaCell's ability to continue as a going concern is explicitly stated to be dependent on its success in securing additional financing.
• High R&D spending without commensurate revenue [medium — operational]: Research and development expenses surged by 82% to $6,683,643 for the three months ended October 31, 2025. This substantial investment in drug development, while necessary, has not yet translated into revenue, contributing to the widening net loss.
• Significant decrease in total assets [medium — financial]: Total assets have fallen from $21,649,706 as of July 31, 2025, to $13,075,050 as of October 31, 2025. This 39% reduction indicates a substantial depletion of the company's asset base, likely due to cash burn.
• FDA approval for Phase 3 trial is a critical milestone [medium — regulatory]: The company's Bria-IMT program has FDA approval for Phase 3 trials in end-stage breast cancer. While positive, the success of this trial is crucial for future development and commercialization, and any setbacks could significantly impact the company.

Industry Context

BriaCell Therapeutics operates in the competitive immuno-oncology sector, focusing on novel cancer immunotherapies. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success hinges on clinical trial outcomes and FDA approvals, with companies often relying on substantial funding to advance pipeline candidates.

Regulatory Implications

The company's Bria-IMT program has received FDA approval for Phase 3 trials, a significant regulatory milestone. However, continued progress is subject to stringent FDA oversight and successful completion of clinical trials. Any adverse findings or delays in regulatory processes could severely impact BriaCell's development timeline and prospects.

What Investors Should Do

1. Monitor cash burn and financing activities closely.
2. Evaluate progress and results of the Phase 3 Bria-IMT trial.
3. Assess the sustainability of R&D spending.

Key Dates

• 2025-10-31: Quarterly period end — Reporting period for the condensed consolidated financial statements, showing increased net loss and decreased cash.
• 2025-07-31: Previous fiscal quarter end — Benchmark for comparison of assets and cash position, showing a significant decline in the current quarter.
• 2025-12-11: Common shares outstanding reported — Indicates 1,883,906 common shares were issued and outstanding as of this date.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. (Shows the company has consistently operated at a loss, reaching $119,953,129 as of October 31, 2025.)

Cash and cash equivalents

Includes cash on hand, bank deposits, and short-term, highly liquid investments with maturities of three months or less. (A critical measure of liquidity; BriaCell's position has significantly decreased to $2,714,012.)

Going concern

An accounting assumption that a business will continue to operate for the foreseeable future. (BriaCell explicitly states its ability to continue as a going concern is dependent on future financing.)

Research and development expenses

Costs incurred in the process of discovering, designing, developing, and improving products or processes. (These expenses have significantly increased to $6,683,643, driving the overall net loss.)

Warrant liability

The fair value of outstanding warrants that are exercisable for the company's stock. (Represents a potential future dilution and a financial obligation, with a balance of $406,873.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, BriaCell Therapeutics Corp. has experienced a significant increase in its net loss, rising by 42% to $8,278,328. This deterioration is primarily driven by an 82% surge in research and development expenses, which climbed to $6,683,643. Concurrently, the company's cash reserves have dwindled substantially, and its total assets have decreased, indicating a challenging financial quarter with increased operational spending and a shrinking asset base.

Filing Documents

• form10-q.htm (10-Q) — 1046KB
• ex31-1.htm (EX-31.1) — 17KB
• ex31-2.htm (EX-31.2) — 17KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-25-027240.txt ( ) — 5765KB
• bctx-20251031.xsd (EX-101.SCH) — 39KB
• bctx-20251031_cal.xml (EX-101.CAL) — 41KB
• bctx-20251031_def.xml (EX-101.DEF) — 222KB
• bctx-20251031_lab.xml (EX-101.LAB) — 298KB
• bctx-20251031_pre.xml (EX-101.PRE) — 271KB
• form10-q_htm.xml (XML) — 1108KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2025 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40101 BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia, Canada 47-1099599 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 235 15 th Street, Suite 300 , West Vancouver , BC , V7T 2X1 (Address of Principal Executive Offices, including zip code) 604 - 921-1810 (Registrant's telephone number, including area code) N/A (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common shares, no par value BCTX The Nasdaq Stock Market LLC Warrants to purchase common shares, no par value BCTXW The Nasdaq Stock Market LLC Warrants to purchase common shares, no par value BCTXZ The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes No As of December 11, 2025, 1,883,906 common shares, no par value per share, of the Company were issued and outstanding. BRIACELL THERAPEUTICS CORP. Form 10-Q Table of Contents Page Part I. Financial Information 3 Item 1. Financial 3 Condensed Consolidated Balance Sheets as of October 31, 2025 (unaudited) and July 31, 2025 (audited) 3 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended October 31, 2025 and 2024 4 Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) for the three months ended October 31, 2025 and 2024 5 Unaudited Condensed Consolidated Statement of Cash Flows for the three months ended October 31, 2025 and 2024 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3. Quantitative and Qualitative Disclosures Regarding Market Risk 21 Item 4. Controls and Procedures 22 Part II. Other Information 24 Item 1. Legal Proceedings 23 Item 1A. Risk Factors 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23 Item 3. Defaults Upon Senior Securities 23 Item 4. Mine Safety Disclosures 23 Item 5. Other Information 23 Item 6. Exhibits 23 Part III. Signatures 24 2 PART I-FINANCIAL INFORMATION Item 1. Financial Statements BRIACELL THERAPEUTICS CORP. CONDENSED CONSOLIDATED BALANCE SHEETS October 31.2025 July 31, 2025 (Unaudited) (Audited) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 2,714,012 $ 10,493,808 Short-term investments 7,461,960 7,372,473 Amounts receivable and prepaid expen ses 1,172,435 2,060,295 Total current assets 11,348,407 19,926,576 NON-CURRENT ASSETS: Equity investment in BC Therapeutics 554,448 524,278 Intangible assets, net 180,707 184,525 Property and equipment, net 273,980 296,819 Long term prepaid expenses 717,508 717,508 Total non-current assets 1,726,643 1,723,130 Total assets $ 13,075,050 $ 21,649,706 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILI

View Full Filing

View this 10-Q filing on SEC EDGAR